# A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

> **NCT05934331** · PHASE2 · RECRUITING · sponsor: **LaNova Medicines Zhejiang Co., Ltd.** · enrollment: 276 (estimated)

## Conditions studied

- Malignant Neoplasms of Digestive Organs

## Interventions

- **DRUG:** LM-302
- **DRUG:** Toripalimab
- **DRUG:** Capecitabine
- **DRUG:** Tegafur, Gimeracil and Oteracil Potassium Capsules
- **DRUG:** Nivolumab
- **DRUG:** Apatinib
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT05934331
- **Lead sponsor:** LaNova Medicines Zhejiang Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-27
- **Primary completion:** 2026-07-01
- **Final completion:** 2028-07-01
- **Target enrollment:** 276 (ESTIMATED)
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05934331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05934331, "A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05934331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*